Inhibiting CD8 T cell infiltration and activation in the early NASH stage can alleviate hepatocyte damage and prevent the activation of immunomodulatory machinery and T cell exhaustion. Here, CD8A is linked to metabolic dysfunction-associated steatohepatitis.